Company insider dossier

Bionano Genomics Inc insider intelligence

BNGO filings assessed for conviction, transaction quality, insider breadth, clustering, freshness, and price confirmation.

Terminal chart Weekly report Factor intelligence Healthcare Medical Instruments & Supplies Data API
77/100

Conviction accumulation

74/100 confidence
Exchange
NASDAQ
Sector
Healthcare
Industry
Medical Instruments & Supplies
Latest evidence
4 Sep 2026

Investment committee read

Conviction accumulation

Priced common-share acquisitions carry more weighted evidence than disposals after freshness, role, size, and duplicate controls.

Research constructive setups

Evidence in favour

  • Participation spans 11 named insiders rather than one filing source.
  • The latest qualifying evidence is fresh, dated 04 Sep 2026.

Decision risks

  • Qualifying disposal events outnumber acquisitions, although disposals receive a lower directional weight.
Conviction77Conviction accumulation
Confidence74Well supported
Named insiders11participating in the tape
Controlled events5directional common-share events
Acquisition value$9.7Knormalized amount
Disposal value$107normalized amount

Price confirmation map

Weekly price with common-share events

Acquisitions and disposals are aligned to the nearest completed weekly bar.

4.523.662.791.931.07 Acquisition · 4 Sep 2026 · $4.8KAcquisition · 21 Aug 2026 · $4.9KDisposal · 3 Jun 2026 · $35Disposal · 3 Jun 2026 · $31Disposal · 3 Jun 2026 · $31Disposal · 3 Jun 2026 · $9
Mar 2025Sep 2026
Weekly closeCommon-share acquisitionCommon-share disposal

Market confirmation

Price and trend context

Latest close
1.22 USD
One-week move
+1.7%
Four-week move
+3.4%
Fair-value gap
-95.5%
Trend signal
Inactive
Relative strength
-20.1

Directional balance

Controlled event mix

40.0%acquisition
Acquisition events
2
Disposal events
3
Net value
$9.6K

Cadence

Twelve-week filing pressure

Volume shows attention. Controlled events determine direction.

029 Jun
006 Jul
013 Jul
020 Jul
027 Jul
403 Aug
010 Aug
117 Aug
024 Aug
131 Aug
007 Sep
014 Sep

Named participants

Insider conviction by person

LUDERER, ALBERTDirector, Interim Chief Executive752 events
BARKER, DAVID LDirector500 events
HASTIE, ALEX REIDChief Scientific Officer500 events
LINNEY, YVONNEDirector500 events
RAJKOVIC, ALEKSANDARDirector500 events
TWOMEY, CHRISTOPHER JDirector500 events
VUORI, KRISTIINA MDDirector500 events
CHAUBEY, ALKACHIEF MEDICAL OFFICER281 events
ADAMCHAK, MARKPrincipal Accounting Officer281 events
DIXON, JONATHAN V.General Counsel281 events
OLDAKOWSKI, MARKChief Operating Officer281 events

Evidence quality

Security and transaction context

Common equity6
Equity compensation0
Options and derivatives9
Other securities0

Role architecture

Who is participating

Other executive8
Director5
CEO and chair2

Transaction evidence

Auditable BNGO filing ledger

Showing 1 to 15 of 15.

LUDERER, ALBERTDirector, Interim Chief Executive
AcquisitionCommon equity
4000 sharesCommon Stock
$4.8KDirectional evidence
LUDERER, ALBERTDirector, Interim Chief Executive
AcquisitionCommon equity
4000 sharesCommon Stock
$4.9KDirectional evidence
ADAMCHAK, MARKPrincipal Accounting Officer
AcquisitionOptions and derivatives
5000 sharesStock Option (Right to Buy)
Not reportedContext evidence
DIXON, JONATHAN V.General Counsel
AcquisitionOptions and derivatives
15000 sharesStock Option (Right to Buy)
Not reportedContext evidence
HASTIE, ALEX REIDChief Scientific Officer
AcquisitionOptions and derivatives
54000 sharesStock Option (Right to Buy)
Not reportedContext evidence
OLDAKOWSKI, MARKChief Operating Officer
AcquisitionOptions and derivatives
15000 sharesStock Option (Right to Buy)
Not reportedContext evidence
OLDAKOWSKI, MARKCHIEF OPERATING OFFICER
DisposalCommon equity
27 sharesCommon Stock
$35Directional evidence
CHAUBEY, ALKACHIEF MEDICAL OFFICER
DisposalCommon equity
24 sharesCommon Stock
$31Directional evidence
DIXON, JONATHAN V.GENERAL COUNSEL
DisposalCommon equity
24 sharesCommon Stock
$31Directional evidence
ADAMCHAK, MARKPrincipal Accounting Officer
DisposalCommon equity
7 sharesCommon Stock
$9Directional evidence
BARKER, DAVID LDirector
AcquisitionOptions and derivatives
9149 sharesStock Option (Right to Buy)
Not reportedContext evidence
LINNEY, YVONNEDirector
AcquisitionOptions and derivatives
9149 sharesStock Option (Right to Buy)
Not reportedContext evidence
RAJKOVIC, ALEKSANDARDirector
AcquisitionOptions and derivatives
9149 sharesStock Option (Right to Buy)
Not reportedContext evidence
TWOMEY, CHRISTOPHER JDirector
AcquisitionOptions and derivatives
9149 sharesStock Option (Right to Buy)
Not reportedContext evidence
VUORI, KRISTIINA MDDirector
AcquisitionOptions and derivatives
9149 sharesStock Option (Right to Buy)
Not reportedContext evidence

Reading the dossier

Direction and confidence are separate

Conviction

The 0 to 100 score classifies deduplicated priced common-share evidence. Fifty is balanced or non-directional.

Confidence

Confidence rises with controlled event depth, named-insider breadth, fresh evidence, normalized values, and a longer observation span.

Disposals

Selling is not treated as the mirror image of buying. It carries less directional weight because taxes, diversification, compensation, and planned transactions can all create sales.

Price confirmation

The market chart tests whether the filing thesis is being confirmed or rejected by price, fair-value position, relative strength, and the current trend state.

Independent market research for education. This classification is not investment advice, a recommendation, a forecast, or an execution instruction.

Evidence context